T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| 1 |
UnitedHealth
UNH
|
$865M |
| 2 |
AbbVie
ABBV
|
$688M |
| 3 |
Intuit
INTU
|
$574M |
| 4 |
Xcel Energy
XEL
|
$466M |
| 5 |
Exelon
EXC
|
$432M |
Top Sells
| 1 |
GE Aerospace
GE
|
$974M |
| 2 |
TE Connectivity
TEL
|
$629M |
| 3 |
Equifax
EFX
|
$338M |
| 4 |
KLA
KLAC
|
$321M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$299M |
Sector Composition
| 1 | Technology | 24.86% |
| 2 | Healthcare | 22.76% |
| 3 | Financials | 12.37% |
| 4 | Consumer Discretionary | 11.76% |
| 5 | Industrials | 11.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Opendoor
OPEN
$3.52B
| $19.1M | 0.01% |
10,876,268
+1,259,853
| +13% | +$2.22M |
|
477
Ventyx Biosciences
VTYX
$174M
| $18.9M | 0.01% |
+564,636
| New | +$18.9M |
|
478
Repare Therapeutics
RPTX
$70M
| $18.8M | 0.01% |
1,912,351
-5,675
| -0.3% | -$55.8K |
|
479
Dayforce
DAY
$11B
| $18.7M | 0.01% |
255,441
-5,675
| -2% | -$416K |
|
480
Nkarta
NKTX
$152M
| $18.4M | 0.01% |
5,177,788
+428,687
| +9% | +$1.52M |
|
481
RGC Resources
RGCO
$226M
| $18.1M | 0.01% |
781,180
-10,975
| -1% | -$255K |
|
482
Hercules Capital
HTGC
$3.53B
| $18.1M | 0.01% |
1,404,876
+23,126
| +2% | +$298K |
|
483
Middleby
MIDD
$6.93B
| $17.3M | 0.01% |
118,285
+1,907
| +2% | +$280K |
|
484
Pool Corp
POOL
$11.4B
| $17.2M | 0.01% |
50,156
-21
| -0% | -$7.19K |
|
485
Badger Meter
BMI
$5.35B
| $16.9M | 0.01% |
138,644
+2,230
| +2% | +$272K |
|
486
Dutch Bros
BROS
$9.28B
| $16.5M | 0.01% |
520,616
-7,969
| -2% | -$252K |
|
487
Kimbell Royalty Partners
KRP
$1.3B
| $16.2M | 0.01% |
1,065,307
-1,370,357
| -56% | -$20.9M |
|
488
Red Robin
RRGB
$115M
| $16.1M | 0.01% |
1,122,744
-1,576
| -0.1% | -$22.6K |
|
489
Advantage Solutions
ADV
$574M
| $15.8M | 0.01% |
10,018,144
+660,623
| +7% | +$1.04M |
|
490
Insteel Industries
IIIN
$738M
| $15.7M | 0.01% |
563,698
| – | – |
|
491
Crinetics Pharmaceuticals
CRNX
$3.01B
| $14.9M | 0.01% |
+929,369
| New | +$14.9M |
|
492
Denali Therapeutics
DNLI
$2.23B
| $14.9M | 0.01% |
647,013
+13,655
| +2% | +$315K |
|
493
Generation Bio
GBIO
$40.5M
| $14.5M | 0.01% |
3,380,956
-196,799
| -6% | -$846K |
|
494
Structure Therapeutics
GPCR
$1.14B
| $14.2M | 0.01% |
+598,108
| New | +$14.2M |
|
|
UMH
495
UMH Properties
UMH
$1.31B
| $14M | 0.01% |
946,826
+109,291
| +13% | +$1.62M |
|
|
XM
496
DELISTED
Qualtrics International Inc. Class A Common Stock
XM
| $13.6M | 0.01% |
764,439
-351,567
| -32% | -$6.27M |
|
497
REX American Resources
REX
$1.03B
| $13.6M | 0.01% |
476,156
-34,227
| -7% | -$979K |
|
498
Arvinas
ARVN
$573M
| $13.4M | 0.01% |
492,180
-660,613
| -57% | -$18M |
|
499
Monte Rosa Therapeutics
GLUE
$308M
| $13.4M | 0.01% |
1,717,065
-217,474
| -11% | -$1.69M |
|
500
HubSpot
HUBS
$24.8B
| $12.6M | 0.01% |
29,300
+445
| +2% | +$191K |
|